Role of ticagrelor in the peri-thrombolytic phase for patients with ST-segment elevation myocardial infarction: a comprehensive review Thromb J . 2024 Oct 11;22(1):90. doi: 10.1186/s12959-024-00658-9 Abstract Recent years have seen ticagrelor, a potent P2Y12 inhibitor, emerge as a significant advancement in the peri-thrombolytic management of patients with ST-segment elevation myocardial infarction (STEMI), offering a promising alternative to traditional antiplatelet drugs like clopidogrel. This...
Oct 31, 2024•2 min
Short-Term Dual Antiplatelet Therapy After Drug-Eluting Stenting in Patients With Acute Coronary Syndromes. A Systematic Review and Network Meta-Analysis JAMA Cardiol. Published online October 9, 2024. doi:10.1001/jamacardio.2024.3216 Abstract Importance : The optimal duration of dual antiplatelet therapy (DAPT) in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI) remains under debate. Objectives: To analyze the efficacy and safety of dual antiplate...
Oct 31, 2024•5 min
Position of Beta-blockers in the Treatment of Hypertension Today: An Indian Consensus J Assoc Physicians India . 2024 Oct;72(10):83-90. doi: 10.59556/japi.72.0715. Abstract Background: Management of essential hypertension (HTN) remains challenging, with contemporary control being achieved in <1/10 of the cases, especially when aligned with the recently updated guidelines of American College of Cardiology (ACC) or International Society of Hypertension (ISH). The place and positioning of beta-b...
Oct 31, 2024•4 min
Antihypertensive therapy in patients with arterial hypertension and concomitant diseases in real clinical practice (according to the National Registry of Arterial Hypertension, 2019–2022) https://doi.org/10.26442/00403660.2024.09.202848 Abstract Background. Arterial hypertension remains the leading risk factor associated with cardiovascular diseases (CVDs), cerebrovascular disease and chronic kidney disease. About 70% of patients with Arterial hypertension who are on monotherapy cannot achieve b...
Oct 31, 2024•5 min
2024 European Society of Cardiology Guidelines for Management of Elevated BP and Hypertension: Key Points European Heart Journal, ehae178, https://doi.org/10.1093/eurheartj/ehae178 The key points to remember from the 2024 European Society of Cardiology (ESC) guidelines for the management of elevated blood pressure (BP) and hypertension are: · The most important point is that the target systolic BP (SBP) for adults receiving BP medications should be 120-129 mm Hg. One can “opt-out” of this goal f...
Sep 30, 2024•5 min
Pulmonary Vein Isolation vs Sham Intervention in Symptomatic Atrial Fibrillation: The SHAM-PVI Randomized Clinical Trial JAMA 2024 Sep 2:e2417921. doi: 10.1001/jama.2024.17921 Abstract Importance: There are concerns that pulmonary vein isolation for atrial fibrillation may have a profound placebo effect, but no double-blind randomized clinical trials have been conducted. Objective: To determine whether pulmonary vein isolation is more effective than a sham procedure for improving outcomes in atr...
Sep 30, 2024•3 min
2024 European Society of Cardiology Guidelines for Management of Chronic Coronary Syndromes: Key Points European Heart Journal, ehae177, https://doi.org/10.1093/eurheartj/ehae177 The key points to remember from the 2024 European Society of Cardiology (ESC) guidelines for the management of chronic coronary syndromes (CCS) are: · The term chronic coronary syndromes describes the clinical presentations of coronary artery disease (CAD) during stable periods, particularly those preceding or following...
Sep 30, 2024•7 min
Transcatheter Valve Repair in Heart Failure with Moderate to Severe Mitral Regurgitation DOI: 10.1056/NEJMoa2314328 Background Whether transcatheter mitral-valve repair improves outcomes in patients with heart failure and functional mitral regurgitation is uncertain. Methods We conducted a randomized, controlled trial involving patients with heart failure and moderate to severe functional mitral regurgitation from 30 sites in nine countries. The patients were assigned in a 1:1 ratio to either tr...
Sep 30, 2024•3 min
Ticagrelor monotherapy in ST-elevation myocardial infarction: An individual patient-level meta-analysis from TICO and T-PASS trials Med. 2024 Aug 10:S2666-6340(24)00301-5. doi: 10.1016/j.medj.2024.07.019. Abstract Background: Patients with ST-elevation myocardial infarction (STEMI) tend to be excluded or under-represented in randomized clinical trials evaluating the effects of potent P2Y12 inhibitor monotherapy after short-term dual antiplatelet therapy (DAPT). Methods: Individual patient data w...
Aug 31, 2024•3 min
Efficacy and Safety of P2Y12 monotherapy vs DAPT in patients undergoing percutaneous coronary intervention: meta-analysis of randomized trials Curr Probl Cardiol. 2024 Aug;49(8):102635. doi: 10.1016/j.cpcardiol.2024.102635 Abstract Background: Debates persist regarding the optimal duration of dual antiplatelet therapy (DAPT) after percutaneous coronary intervention (PCI) in coronary artery disease (CAD). Recent trials have introduced a novel approach involving P2Y12 inhibitor monotherapy with ti...
Aug 31, 2024•3 min
Early postoperative beta-blockers are associated with improved cardiac output after late complete repair of tetralogy of Fallot: a retrospective cohort study Eur J Pediatr. 2024 Aug;183(8):3309-3317. doi: 10.1007/s00431-024-05597-1. Abstract Tetralogy of Fallot is the most common cyanotic congenital heart disease. For decades, our institution has cared for humanitarian patients with late presentation of tetralogy of Fallot. They are characterized by severe right ventricular hypertrophy with cons...
Aug 31, 2024•3 min
Eligibility and Projected Benefits of Rapid Initiation of Quadruple Therapy for Newly Diagnosed Heart Failure JACC Heart Fail. 2024 Aug;12(8):1365-1377. doi: 10.1016/j.jchf.2024.03.001. Abstract Background: U.S. nationwide estimates of the proportion of patients newly diagnosed with heart failure with reduced ejection fraction (HFrEF) eligible for quadruple medical therapy, and the associated benefits of rapid implementation, are not well characterized. Objectives: This study sought to character...
Aug 31, 2024•4 min
Non-ST-elevation acute coronary syndromes with previous coronary artery bypass grafting: a meta-analysis of invasive vs. conservative management Eur Heart J . 2024 Jul 12;45(27):2380-2391. doi: 10.1093/eurheartj/ehae245 Abstract Background and aims : A routine invasive strategy is recommended in the management of higher risk patients with non-ST-elevation acute coronary syndromes (NSTE-ACSs). However, patients with previous coronary artery bypass graft (CABG) surgery were excluded from key trial...
Jul 31, 2024•3 min
Verification of haemoglobin level to prevent worsening of prognosis in heart failure with preserved ejection fraction patients from the PURSUIT-HFpEF registry https://doi.org/10.1002/ehf2.14927 Abstract Aim Anaemia has been reported as poor predictor in heart failure with preserved ejection fraction (HFpEF). The aim of this study was to evaluate the impact of changes in haemoglobin (Hb) from discharge to 1 year after discharge on the prognosis using a lower cut-off value of Hb than the World Hea...
Jul 31, 2024•4 min
Ticagrelor downregulates the expression of proatherogenic and proinflammatory micro RNA 125-b compared to clopidogrel: A randomized, controlled trial Int J Cardiol . 2024 Jul 1:406:132073 Abstract Background: Platelet P2Y12 antagonist ticagrelor reduces cardiovascular mortality after acute myocardial infarction (AMI) compared to clopidogrel, but the underlying mechanism is unknown. Because activated platelets release proatherogenic and proinflammatory microRNAs, including microRNA -125a, microRN...
Jul 31, 2024•3 min
Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2D6, ADRB1, ADRB2, ADRA2C, GRK4, and GRK5 Genotypes and Beta-Blocker Therapy Clin Pharmacol Ther. 2024 Jul 1. doi: 10.1002/cpt.3351 Abstract Beta-blockers are widely used medications for a variety of indications, including heart failure, myocardial infarction, cardiac arrhythmias, and hypertension. Genetic variability in pharmacokinetic (e.g., CYP2D6) and pharmacodynamic (e.g., ADRB1, ADRB2, ADRA2C, GRK4, GRK5) genes hav...
Jul 31, 2024•2 min
The new ESC acute coronary syndrome guideline and its impact in the CPU and emergency department setting Herz. 2024 Jun;49(3):185-189. doi: 10.1007/s00059-024-05241-6 The new guideline on acute coronary syndrome (ACS) of the European Society of Cardiology (ESC) replaces two separate guidelines on ST-elevation myocardial infarction (STEMI) and non-ST-elevation (NSTE) ACS . This change of paradigm reflects the experts view that the acute coronary syndrome is a continuum,starting with unstable angi...
Jun 30, 2024•2 min
Coronary Atherosclerotic Plaque Activity and Risk of Myocardial Infarction J Am Coll Cardiol. 2024 Jun 4;83(22):2135-2144 Abstract Background: Total coronary atherosclerotic plaque activity across the entire coronary arterial tree is associated with patient-level clinical outcomes. Objectives: We aimed to investigate whether vessel-level coronary atherosclerotic plaque activity is associated with vessel-level myocardial infarction. Methods: In this secondary analysis of an international multicen...
Jun 30, 2024•2 min
Antiplatelet therapy after coronary artery bypass surgery: five year follow-up of randomised Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting trial BMJ . 2024 Jun 11:385:e075707. doi: 10.1136/bmj-2023-075707. Abstract Objective: To assess the effect of different antiplatelet strategies on clinical outcomes after coronary artery bypass grafting. Design : Five year follow-up of randomised Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Grafting (DA...
Jun 30, 2024•3 min
Ticagrelor with or without aspirin following percutaneous coronary intervention in high-risk patients with concomitant peripheral artery disease: A subgroup analysis of the TWILIGHT randomized clinical trial Am Heart J. 2024 Jun:272:11-22. doi: 10.1016/j.ahj.2024.03.002 Abstract Background: The optimal antiplatelet regimen after percutaneous coronary intervention (PCI) in patients with peripheral artery disease (PAD) is still debated. This analysis aimed to compare the effect of ticagrelor monot...
Jun 30, 2024•3 min
Tolerability and effectiveness of beta-blockers in patients with cardiac amyloidosis: A systematic review and meta-analysis Int J Cardiol . 2024 May 1:402:131813. doi: 10.1016/j.ijcard.2024.131813 Abstract Objective: This systematic review aimed to assess the tolerability of patients with cardiac amyloidosis (CA) to beta-blockers (BBs) and evaluate its association with adverse outcomes. Methods: We performed a comprehensive search from January 1, 2000 to October 20, 2023. Studies examining BB us...
May 31, 2024•3 min
Ticagrelor alone versus ticagrelor plus aspirin from month 1 to month 12 after percutaneous coronary intervention in patients with acute coronary syndromes (ULTIMATE-DAPT): a randomized, placebo-controlled, double-blind clinical trial Randomized Controlled Trial Lancet . 2024 May 11;403(10439):1866-1878. doi: 10.1016/S0140-6736(24)00473-2. Abstract Background: Following percutaneous coronary intervention with stent placement to treat acute coronary syndromes, international clinical guidelines ge...
May 31, 2024•5 min
Obesity is associated with acute kidney injury in ST-segment-elevation myocardial infarction undergoing percutaneous coronary intervention: A national representative cohort study Catheter Cardiovasc Interv . 2024 May;103(6):897-908. doi: 10.1002/ccd.31030 Abstract Background: Acute kidney injury (AKI) is a frequent and potentially life-threatening complication after percutaneous coronary intervention (PCI) in patients with ST-segment-elevation myocardial infarction (STEMI). However, the relation...
May 31, 2024•3 min
Management of Severe Mitral Regurgitation in Patients With Acute Myocardial Infarction: JACC Focus Seminar 2/5 J Am Coll Cardiol . 2024 May 7;83(18):1799-1817. doi: 10.1016/j.jacc.2023.09.840 Abstract Severe acute mitral regurgitation after myocardial infarction includes partial and complete papillary muscle rupture or functional mitral regurgitation. Although its incidence is <1%, mitral regurgitation after acute myocardial infarction frequently causes hemodynamic instability, pulmonary edem...
May 31, 2024•2 min
Ticagrelor was associated with lower fracture risk than clopidogrel in the dual anti-platelet regimen among patients with acute coronary syndrome treated with percutaneous coronary intervention J Endocrinol Invest. 2024 Apr;47(4):895-902. doi: 10.1007/s40618-023-02205-1 Abstract Purpose: Patients with coronary artery disease have increased fracture risks. P2Y12 inhibitors may impact fracture risks. We compared the fracture risks associated with ticagrelor and clopidogrel in dual anti-platelet th...
Apr 30, 2024•3 min
The application value of Metoprolol combined with Dagalizin in enhancing cardiac function and ventricular remodeling in patients with acute myocardial infarction after percutaneous coronary intervention. J Clin Emerg, 2024, 25(4): 170-174. doi: 10.13201/j.issn.1009-5918.2024.04.003 Abstract To discuss the application value of metoprolol combined with daglizin in improving cardiac function and ventricular remodeling in patients with acute myocardial infarction(AMI) after percutaneous coronary int...
Apr 30, 2024•3 min
Prognostic Impact of Early Administration of β-Blockers in Critically Ill Patients with Acute Myocardial Infarction J Clin Pharmacol . 2024 Apr;64(4):410-417. doi: 10.1002/jcph.2370. Abstract In critically ill patients with acute myocardial infarction (AMI), the relationship between the early administration of β-blockers and the risks of in-hospital and long-term mortality remains controversial. Furthermore, there are conflicting evidences for the efficacy of the early administration of intraven...
Apr 30, 2024•3 min
Impact of cardiac rehabilitation on ventricular-arterial coupling and left ventricular function in patients with acute myocardial infarction PLoS One . 2024 Apr 4;19(4):e0300578. doi: 10.1371/journal.pone.0300578 Abstract To maintain efficient myocardial function, optimal coordination between ventricular contraction and the arterial system is required. Exercise-based cardiac rehabilitation (CR) has been demonstrated to improve left ventricular (LV) function. This study aimed to investigate the i...
Apr 30, 2024•3 min
2024 ACC Expert Consensus Decision Pathway for Treatment of Heart Failure With Reduced Ejection Fraction: A Report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol 2024;Mar 8:[Epub ahead of print]. In line with recent evidence and guidelines, the recommended core guideline-directed medical therapy (GDMT) for chronic heart failure (HF) includes an angiotensin II receptor/neprilysin inhibitor (ARNI), evidence-based beta-blocker, sodium-glucose cotransporter...
Mar 31, 2024•3 min
P2Y12 Inhibitor Monotherapy vs Dual Antiplatelet Therapy After Deployment of a Drug-Eluting Stent: The SHARE Randomized Clinical Trial JAMA Netw Open. 2024 Mar 4;7(3):e240877 Abstract Importance: P2Y12 inhibitor monotherapy after dual antiplatelet therapy (DAPT; a P2Y12 inhibitor plus aspirin) for a brief duration has recently emerged as an attractive alternative for patients undergoing percutaneous coronary intervention with a drug-eluting stent. Objective: To investigate whether P2Y12 inhibito...
Mar 31, 2024•4 min
